ArticleBiosensors2026
Enhancing the Detection of Long-Chain Aldehydes by Peptide-Based Biosensors Through Counter-Ion Exchange.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Long-chain aldehydes, particularly nonanal, are recognized as potential volatile biomarkers of lung cancer in exhaled breath. This study investigates the influence of peptide counter-ions on the performance of QCM-based biosensors using two odorant-binding protein-derived peptides (OBPP4 and OBPP4 GSGSGS) for the selective gas-phase detection of these aldehydes. Exchanging the counter-ion from trifluoroacetate to chloride improves biosensor sensitivity and lowers the limit of detection within the set of biosensors investigated in this study. The OBPP4 GSGSGS with chloride exhibited the highest sensitivity to nonanal (0.153 Hz/ppm) and the lowest LOD (9.8 ppm), with excellent selectivity over other groups of volatiles. The novelty of this work lies in demonstrating, for the first time, that simple counter-ion exchange in synthetic peptides can significantly enhance the gas-phase binding of volatile aldehydes, classified as lung cancer biomarkers, without altering the peptide sequence, offering a straightforward and effective optimization strategy for peptide-based piezoelectric biosensors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.